Condition: Solid Tumor, Adult · Sponsor: Grit Biotechnology
Expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors)，3 dose groups.A modified "3+3" dose-escalation design is utilized,This includes both accelerated dose escalation and traditional "3+3" dose escalation.The first dose group is accelerated titration,The first dose group is an accelerated titration of 1 to 6 evaluable subjects;The second and third dose groups are based on the traditional "3+3" dose-escalation principle,The second and third dose groups are based on the traditional "3+3" dose-escalation principle, with 3 to 6 evaluable subjects enrolled respectively.
This description comes directly from the study's public registry record.
Yongsheng Wang, PHD · +86 18980602258 · wangys@wchscu.cn
Always discuss trial participation with your own doctor first.
| The fifth medical center of the General Hospital of the Chinese people's Liberation Army | Beijing, Beijing Municipality, China | Recruiting |
| Union Hospital Tongji Medical College Huazhong University Of Science And Technology | Wuhan, Hubei, China | Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Recruiting |
| West China Hospital Sichuan University | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06144671